Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-23-125216
Filing Date
2023-04-28
Accepted
2023-04-28 11:15:59
Documents
6
Period of Report
2023-06-07

Document Format Files

Seq Description Document Type Size
1 DEF 14A d464571ddef14a.htm DEF 14A 554391
2 GRAPHIC g464571g01a01.jpg GRAPHIC 78856
3 GRAPHIC g464571g02a02.jpg GRAPHIC 632077
4 GRAPHIC g464571g30h04.jpg GRAPHIC 23027
5 GRAPHIC g464571page061.jpg GRAPHIC 150411
6 GRAPHIC g464571page062.jpg GRAPHIC 108511
  Complete submission text file 0001193125-23-125216.txt   1907683
Mailing Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021
Business Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021 425-686-1500
ACHIEVE LIFE SCIENCES, INC. (Filer) CIK: 0000949858 (see all company filings)

EIN.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 033-80623 | Film No.: 23861784
SIC: 2835 In Vitro & In Vivo Diagnostic Substances